Alopecia Areata, Atopic Dermatitis, Chronic Spontaneous Urticaria, Hidradenitis Suppurativa, Psoriasis, Vitiligo
Conditions
Keywords
Atopic Dermatitis, IMISC, Registry, Observational, Immune-mediated Inflammatory Skin Conditions
Brief summary
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Detailed description
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies. The duration of follow-up for participants enrolled in the EU is limited to 5-years. Those within in US and Canada may consent to indefinite follow-up.
Interventions
None listed
Sponsors
Target PharmaSolutions, Inc.
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* 1\. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment. * 2\. Participant has plans for future visits at the site for continued management of IMISC.
Exclusion criteria
* 1\. Inability to provide written informed consent/assent. * 2\. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characterize IMISC Treatment Regimens in Clinical Practice | 25 Years | Enable characterization of IMISC disease activity and comorbid medical conditions over time. |
| Evaluate Patient Outcomes in Clinical Practice | 25 Years | Enable characterization of IMISC disease activity and comorbid medical conditions over time. |
| Evaluate Adverse Events of IMISC and treatment in Clinical Practice | 25 Years | Enable characterization of IMISC disease activity and comorbid medical conditions over time. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the relationship between IMISC and comorbid medical conditions | 25 Years | Inform clinical practice by identifying the occurrence and impact of comorbid medical conditions on treatment regimens, utilize patient reported outcomes, and evaluate patient support programs. |
| Evaluate Patient Reported Outcome (PRO) measures | 25 Years | Inform clinical practice by identifying the occurrence and impact of comorbid medical conditions on treatment regimens, utilize patient reported outcomes, and evaluate patient support programs. |
| Evaluate outcomes related to Patient Support Programs (PSPs) | 25 Years | Inform clinical practice by identifying the occurrence and impact of comorbid medical conditions on treatment regimens, utilize patient reported outcomes, and evaluate patient support programs. |
Countries
Canada, Germany, Spain, United States
Contacts
STUDY_DIRECTORLaura Dalfonso
Target RWE
Outcome results
None listed